Thulium vapoenucleation of the prostate (ThuVEP) has been introduced as a minimally invasive treatment for benign prostatic obstruction (BPO).
To analyze immediate outcomes and the institutional learning curve of ThuVEP, and to report its standardized complication rates, using the modified Clavien classification system (CCS) to grade perioperative complication rates.
Design, settings, and participants
A prospective evaluation of 1080 patients undergoing ThuVEP from January 2007 until May 2012 at our institution.
ThuVEP was performed using the 2-μm, continuous-wave, thulium:yttrium-aluminum-garnet laser.
Outcome measurements and statistical analysis
Preoperative status, surgical details, and immediate outcome were recorded for each patient. Perioperative complications were classified according to the modified CCS.
Results and limitations
Median prostate size was 51
ThuVEP is a safe and effective procedure for the treatment of symptomatic BPO, with low perioperative morbidity.
Keywords: Benign prostatic obstruction, Morbidity, Mortality, Tm:YAG, ThuVEP, Thulium vapoenucleation of the prostate, Vapoenucleation.
a Asklepios Hospital Barmbek, Department of Urology, Hamburg, Germany
b UMM, University Medical Center Mannheim, Department of Urology, Mannheim, Germany
These authors contributed equally to this research.
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.
© 2012 European Association of Urology, Published by Elsevier B.V.